There are currently no centrally held data on the number of people in the United Kingdom who use an insulin pump. We are unable to provide a direct comparison to the number of people using insulin pumps in other parts of Europe or the United States.
The uptake of insulin pumps in the UK is known to be lower than in most other countries of comparable economic standing and level of healthcare provision.
The NHS Technology Adoption Centre is currently investigating the barriers to the adoption of insulin pumps. Their guidance is due to be published at the end of April 2010.
The National Institute for Health and Clinical Excellence (NICE) assesses the cost and benefits of treatments and provides guidance on best practice. We expect all clinicians to consider NICE guidance when making decisions with patients (and/or their parents or carer) about an individual's care pathway.
NICE guidance recommends pump therapy as an option for adults and children of 12 years and older with type 1 diabetes, provided that multiple-dose insulin therapy had failed and that those receiving the treatment could use it effectively.
NICE also recommends that insulin pump therapy can be used as a treatment option for children younger than 12 years with type 1 diabetes, provided that: Multiple daily injection (MDI) therapy is considered to be impractical or inappropriate. Children on insulin pumps would be expected to undergo a trial of MDI therapy between the ages of 12 and 18 years.
There are no centrally held data on the number of people in the United Kingdom that use a continuous glucose monitor either self-funded or funded by the National Health Service.
The National Institute for Health and Clinical Excellence (NICE) recommends that children and young people with type 1 diabetes who have persistent problems with glyceamic control should be offered continuous glucose monitoring systems.
We expect all clinicians to consider NICE guidance when making decisions with patients (and/or their parents or carer) about an individual's care pathway.